Delayed Nasdaq  -  04:00 2022-08-19 pm EDT
1.590 USD   +2.58%
08/17MAGENTA THERAPEUTICS : Appoints Michael Vasconcelles, M.D. to the Board of Directors - Form 8-K
08/17MAGENTA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
08/17Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Magenta Therapeutics : Announces $86.4 Million Common Stock Investment from Multiple Investors

05/12/2021 | 10:01am EDT

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has agreed to sell approximately 9,600,000 shares of its common stock to certain institutional investors in a private placement. Magenta anticipates aggregate gross proceeds from the offering will be $86.4 million, before deducting estimated offering expenses payable by the Company, based on the offering price of $9.00 per share. The financing syndicate includes Deep Track Capital, L.P., TCG X, Great Point Partners, LLC, OrbiMed and Janus Henderson Investors. The closing is anticipated to occur on May 14, 2021, subject to customary closing conditions. Magenta intends to use the net proceeds from the offering for general corporate purposes and working capital.

The securities are being sold in a private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Company has agreed to file a resale registration statement with the Securities and Exchange Commission (the “SEC”), for purposes of registering the resale of the shares of common stock issued or issuable in connection with the offering.

Important Information

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The use of words such as “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” or the negative of such words or other similar expressions can be used to identify forward-looking statements. Any forward-looking statements included in this press release, such as statements regarding the expected timing for the closing of the private placement and the anticipated use of proceeds from the private placement, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and the completion of the private placement on the anticipated terms, or at all. These and other risks and uncertainties are described in additional detail in the section entitled “Risk Factors” in Magenta’s Annual Report on Form 10-K filed on March 3, 2021, as updated by its Quarterly Reports on Form 10-Q and its other filings made with the SEC from time to time. Although Magenta's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Magenta. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Magenta undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

© Business Wire 2021
08/17MAGENTA THERAPEUTICS : Appoints Michael Vasconcelles, M.D. to the Board of Directors - For..
08/17MAGENTA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disc..
08/17Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
08/17Magenta Therapeutics Announces Appointment of Michael Vasconcelles to its Board of Dire..
08/04Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Mont..
08/04MAGENTA THERAPEUTICS : Reports Second Quarter Financial Results and Recent Program Highlig..
08/04Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highli..
08/02Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Hea..
06/30MAGENTA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K..
More news
Analyst Recommendations on MAGENTA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -76,4 M - -
Net Debt 2022 7,95 M - -
P/E ratio 2022 -1,28x
Yield 2022 -
Capitalization 92,9 M 92,9 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 70
Free-Float 92,0%
Duration : Period :
Magenta Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MAGENTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,59 $
Average target price 5,00 $
Spread / Average Target 214%
EPS Revisions
Managers and Directors
Jason Gardner President, Chief Executive Officer & Director
Stephen Frank Mahoney COO, CFO, Treasurer & Chief Accounting Officer
Alison Francis Lawton Chairman
Lisa M. Olson Chief Scientific Officer & Head-Research
David Nichols Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-10.01%81 694
WUXI APPTEC CO., LTD.-23.76%38 898
BIONTECH SE-42.74%35 872